Introduction
The crosstalk between neovascular endothelial cells and tumor cells plays a major role in oral squamous cell carcinoma (OSCC) tumor growth and angiogenesis (1) (2) (3) . We have reported that Bcl-2 is a key regulator of this crosstalk (1, 2) and have reported a novel role for Bcl-2 as a pro-angiogenic signaling molecule (4) . However, the functional implications of the molecular interactions between lymphatic endothelial cells and OSCC cells are not clearly understood. Considering that OSCC frequently metastasize to the lymph nodes, a better understanding of the crosstalk between lymphatic endothelial cells and OSCC may lead to new therapies and to significant improvements in the management of patients with oral cancer.
It has been reported that vascular endothelial growth factor (VEGF)-C and its cognate receptor VEGFR-3 are expressed in head and neck squamous cell carcinomas (5) . VEGF-C binds primarily to VEGFR-3, inducing lymphangiogenesis (6) and regulating several cellular functions involved in cancer progression (5, (7) (8) (9) . Once activated, VEGFR-3 is phosphorylated and triggers signaling through the PI3k ⁄ Akt pathway (10, 11) . The activation of the PI3k ⁄ Akt pathway can induce Bcl-2 expression in vascular endothelial cells (12) . However, the role of the PI3k ⁄ Akt pathway in the regulation of VEGF-C-induced Bcl-2 expression in lymphatic endothelial cells remains unclear.
This study was designed to examine signaling pathways involved in the regulation of Bcl-2 in lymphatic endothelial cells, and to evaluate the impact of endothelial cell Bcl-2 expression in primary tumors on lymph node metastasis. Our results suggest that Bcl-2 expression levels in primary tumor-associated endothelial cells are correlated with the incidence of lymph node metastasis in patients with OSCC. Furthermore, this work revealed that VEGF-C induces Bcl-2 expression in lymphatic endothelial cells via VEGFR-3 signaling through the PI3k ⁄ Akt pathway.
Materials and methods

Cell culture
Primary human dermal lymphatic microvascular endothelial cells (HMVEC) and human dermal microvascular endothelial cells (HDMEC) were obtained from Lonza (Walkersville, MD, USA) and cultured in EGM-2 MV (Lonza). The human oropharyngeal SCC cell lines (UM-SCC-11A, UM-SCC-11B, UM-SCC-17A, gift from Dr. T. Carey, University of Michigan) were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and penicillin ⁄ streptomycin.
Western blots VEGF-C and VEGFR-3 baseline expression levels were evaluated by Western blots using polyclonal anti-human VEGF-C and anti-human VEGFR-3 antibodies, respectively (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Furthermore, HMVEC and HDMEC were serum-starved overnight, pretreated with 0-30 lM LY294002 (Sigma-Aldrich, St. Louis, MO, USA) for 1 h, and then treated with 0-50 ng ⁄ ml rhVEGF-C (R & D Systems, Minneapolis, MN, USA) for 24 hours in the presence of LY2964002. Alternatively, HMVEC were exposed to serum-free conditioned media collected from the SCC cell lines for 24 h. The role of VEGFR-3 in VEGF-C-induced Bcl-2 expression was evaluated with 0-10 lg ⁄ ml anti-human VEGFR-3 neutralizing antibody (Santa Cruz). Bcl-2 expression was evaluated by Western blot with the hamster anti-human Bcl-2 (BD Biosciences, San Jose, CA, USA), and phosphorylated and total Akt expression was also analyzed with respective polyclonal anti-human antibodies (Cell Signaling, Beverly, MA, USA).
LCM and RT-PCR from human OSCC Six cases of OSCC with known clinical outcomes were studied here (Table 1) . They included three metastatic (M+ OSCC) and three non-metastatic (M) OSCC) tumors. The limited number of cases in each group is explained by the fact that the samples included in this study strictly met the following inclusion criteria: (A) they should be retrieved from patients who had surgical neck resection and lymph node immunohistochemical confirmation with analysis for cytokeratins (Fig. 1) ; and (B) the laser capture microdissection (LCM)-retrieval should generate at least 1500 endothelial cells and 10 000 tumor cells located exclusively in the advancing tumor front. Immunohistochemical staining for Factor VIII (1:500; Neomarkers, Fremont, CA, USA) was performed to identify vascular endothelial cells in preparation for the LCM, as described (1) . Endothelial cells and tumor cells were retrieved from each tissue section from the three independent tumors and pooled for RT-PCR analysis according to each experimental condition. Total RNA was isolated using Trizol reagent (Invitrogen) and purified with RNAeasy Mini Kits (Qiagen Inc., Valencia, CA, USA). SuperScript one-step reverse-transcription-PCR (RT-PCR) was performed using the Platinum Taq kit (Invitrogen). The following are the primer sequences: E-cadherin (sense 5¢-TGGAC AGGGAGGATTTTGAG-3¢; antisense 5¢-CTTGAGC CCCAGAGTTTGAG-3¢; 385 bp amplicon); Bcl-2 (sense 5¢-CTGCGAAGAACCTTGTGTGA-3¢; antisense 5¢-TGTCCCTACCAACCAGAAGG-3¢; 214 bp amplicon); and GAPDH sense 5¢-CATGGCCTCCAA GGAGTAAG-3¢; antisense 5¢-AGGGGTCTACAGGC AACTG-3¢; 683 bp).
Results
Bcl-2 expression in the endothelial cells of metastatic tumors A stepwise method was used to selectively retrieve endothelial cells or OSCC cells from paraffin-embedded tissue sections (Fig. 2) . The first step aims at the elimination of luminal contents (Fig. 2B ). This is followed by retrieval of tumor-associated endothelial cells (Fig. 2C) , and retrieval of tumor cells (Fig. 2D ). This method results in a relatively pure RNA preparation, as demonstrated by the analysis of E-cadherin expression, a well-known marker for cells with epithelial origin (Fig. 2E,F; Fig. S1 ). Indeed, while the tumor cell RNA preparations showed strong positive expression of E-cadherin, the endothelial cell RNA preparations did not. Once the purity of the RNA preparations was confirmed, we evaluated Bcl-2 expression levels in the endothelial cells of tumors from patients with or without lymph node metastasis. We observed that Bcl-2 was Table 1 Personal data, staging, histological grade, and number of metastatic lymph nodes in the oral squamous cell carcinoma cases evaluated here. These tumors were located in the tongue and ⁄ or floor of the mouth, as determined by clinical and histological evaluation strongly expressed in tumor-associated endothelial cells of patients with metastasis, but not in patients without metastasis (Fig. 2E) . Interestingly, Bcl-2 expression was undetectable in the OSCC cells (Fig. 2F) .
VEGF-C signals through VEGFR-3 to induce Bcl-2 in lymphatic endothelial cells To understand potential mechanisms regulating Bcl-2 in lymphatic endothelial cells, we studied the activity of the VEGF-C and VEGFR-3 signaling pathways. While lymphatic endothelial cells strongly express VEGFR-3, vascular endothelial cells and three OSCC cell lines did not express this receptor (Fig. 3A) . In contrast, all cells examined here expressed VEGF-C (Fig. 3A) . Bcl-2 expression was potently induced by rhVEGF-C in lymphatic endothelial cells (Fig. 3B) . The growth factor milieu secreted by OSCC potently induced Bcl-2 expression in lymphatic endothelial cells (Fig. 3C) . Notably, VEGF-C-induced Bcl-2 expression is mediated by VEGFR-3 signaling in lymphatic endothelial cells (Fig. 3D ).
Akt mediates VEGF-C-induced Bcl-2 expression in lymphatic endothelial cells
To evaluate the role of Akt on the regulation of Bcl-2 expression in lymphatic endothelial cells, we used LY294002, an inhibitor of the PI3k-Akt signaling. VEGF-C induced rapid and potent phosphorylation of Akt in lymphatic endothelial cells (Fig. 4A ). As expected, LY294002 blocked VEGF-C-induced Akt phosphorylation in these cells (Fig. 4A) . Blockade of Akt phosphorylation abrogated VEGF-C-induced Bcl-2 expression in lymphatic endothelial cells, demonstrating the requirement of Akt signaling in this process (Fig. 4B) . In contrast, VEGF-C had no effect on Akt phosphorylation and Bcl-2 expression in dermal endothelial cells (Fig. 4A,B ).
Discussion
It is well known that the control of loco-regional disease constitutes a major challenge in the management of patients with oral cancer. A complicating factor is that very little is known about the mechanisms underlying the displacement of OSCC from the primary tumor site and the beginning of the cellular processes that result in lymph node metastasis. Lymphatic vessels can be found within certain cancer types (13, 14) . Notably, emerging evidence has shown that cancer cells invade into local lymph nodes mainly via peritumoral lymphatic vessels (15) . It has been recently shown that the crosstalk between cancer cells and lymphatic endothelium induces changes in the lymphatics that may contribute to metastatic spread (16) . Indeed, lymphatic endothelial cells activated by highly metastatic cancer cells displayed aberrant behaviors and secrete chemokines that facilitate cancer cell migration (17) . Here, we observed that Bcl-2 is highly expressed in tumor-associated endothelial cells of oral cancer patients with lymph node metastasis, while it is undetectable in the endothelial cells of patients that did not metastasize. These findings enhance the understanding of mechanisms of OSCC metastasis and may have implications to the clinical management of patients with oral cancer. We have previously shown that endothelial cell Bcl-2 signaling promotes head and neck tumor growth (1) and induces tumor cell motility via the CXC chemokine pathway (18) . These findings provided the rationale for the current exploration of the role of endothelial cell Bcl-2 on the metastatic spread of head and neck Western blot to determine the role of VEGFR-3 on VEGF-C-induced Bcl-2 in lymphatic endothelial cells. Cells were exposed to 10 ng ⁄ ml rhVEGF-C in the presence of increasing concentrations of neutralizing anti-VEGFR3 antibody.
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squamous cell carcinomas (HNSCC). Since we found that endothelial cell Bcl-2 expression levels were correlated with lymph node metastasis, and assuming that lymph node metastases would be primarily driven by invasion through lymphatic vessels, we focused the mechanistic studies included here on the analyses of lymphatic endothelial cells, using vascular endothelial cells as controls. We observed that all OSCC cell lines evaluated here express VEGF-C. VEGF-C expression has been correlated with lymphatic metastatic potential and invasiveness of cancer cells (18) (19) (20) (21) . Zhuang et al. have shown that VEGF-C is expressed by highly metastatic OSCC cells (16, 17) . We observed that VEGF-C, as well as the growth factor milieu secreted by several OSCC cell lines, induced Bcl-2 expression in lymphatic endothelial cells. These data are in line with the observation that VEGF-C induces the survival of leukemic tumor cells (7) . Notably, the VEGF-C ⁄ VEG-FR3 axis activation has been associated with lymphangiogenesis (19), angiogenesis (22) , and endothelial cell survival (23) . Collectively, these observations suggest that VEGF-C augments the lymphatic component of oral tumors by enhancing the Bcl-2 expression in the lymphatic endothelial cells. It has been shown that VEGF-C activates the PI3k ⁄ Akt pathway through VEGFR3 (7, 10) . Here, we showed that VEGF-C induces Akt phosphorylation and Bcl-2 expression in VEGFR3-expressing lymphatic endothelial cells, but not in dermal endothelial cells that do not express VEGFR3. These data suggest that the effects of VEGF-C on Bcl-2 are specific to the lymphatic system. Further, we observed that signaling through VEGFR3 and the phosphorylation of Akt are required for Bcl-2 expression in lymphatic endothelial cells. Collectively, these findings unveil a pathway for the regulation of lymphatic endothelial cell survival that is orchestrated by Bcl-2.
The gene expression analysis performed with cells retrieved from human OSCC provides clinical relevance to our laboratory results. Tumor-associated endothelial cells from metastatic OSCC cases expressed Bcl-2, while the endothelial cells from the tumors of patients that did not exhibit metastasis did not express Bcl-2. To the best of our knowledge, this is the first demonstration of a correlation between primary tumor-associated endothelial cell Bcl-2 expression and the presence of lymph node metastasis. We speculate that Bcl-2 may contribute to the metastatic spread to lymph nodes by the following: (i) Increasing the survival of tumor-associated endothelial cells in OSCC; (ii) Triggering signaling pathways that result in enhanced secretion of chemotactic factors by endothelial cells; and (iii) Enhancing the invasive phenotype of OSCC cells. Notably, we have demonstrated that Bcl-2 induces expression of CXCL1 and CXCL8 in vascular endothelial cells (4) and that these factors signal through CXCR2 to enhance the invasiveness of head and neck squamous cell carcinoma cells (18) . Our laboratory is currently performing studies to better understand the functional role of Bcl-2 in tumorassociated lymphatic endothelial cells.
Taken together, our results unveiled a signaling pathway that may have significant implications to the regulation of lymphangiogenesis and metastatic spread of oral cancers (Fig. 5) . These studies suggest that Bcl-2 
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